Figure 1From: Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial CONSORT diagram showing patient disposition through the phase I and phase II trials. Back to article page